[

covishield

]
PAGE 9

Ahead of world's 'biggest vaccination programme', PM Modi to meet CMs tomorrow

To track people above 50 years, the latest electoral roll for Lok Sabha and Legislative Assembly elections will be used.
Prime Minister Narendra Modi will interact with CMs before vaccination begins from January 16.(PTI)
Prime Minister Narendra Modi will interact with CMs before vaccination begins from January 16.(PTI)
Updated on Jan 10, 2021 03:00 PM IST
Copy Link
By hindustantimes.com | Edited by Poulomi Ghosh

2nd vaccination dry run across the country today: All you need to know

Uttar Pradesh, Haryana and Arunachal Pradesh will not be participating in this dry run as they have already conducted them in all their districts.
A dry run was carried out in eight districts on December 28-29 and the first countrywide drill covering 74 districts was held on January 2.(Dheeraj Dhawan / Hindustan Times)
A dry run was carried out in eight districts on December 28-29 and the first countrywide drill covering 74 districts was held on January 2.(Dheeraj Dhawan / Hindustan Times)
Updated on Jan 08, 2021 07:20 AM IST
Copy Link
Hindustan Times, New Delhi | By hindustantimes.com | Edited by Prashasti Singh

Application in Pune court against trade mark of “Covishield”

HT Image
HT Image
Published on Jan 05, 2021 11:37 PM IST
Copy Link
Hindustan Times, Pune | By Shalaka Shinde, Pune

Second dose of Covishield vaccine should be administered between four to six weeks: DCGI

DGCI said that the second dose should be administered between four to six weeks after the first dose and also noted that there is data available for administration of the second dose up to 12 weeks after the first dose from the overseas studies.
The permission document also states that the firm should ensure that “factsheet for the vaccine recipient or attendant is provided prior to administration of vaccine”.(REUTERS)
The permission document also states that the firm should ensure that “factsheet for the vaccine recipient or attendant is provided prior to administration of vaccine”.(REUTERS)
Published on Jan 04, 2021 06:51 PM IST
Copy Link
New Delhi | By Asian News International | Posted by Srivatsan K C

After Covishield and Covaxin, these are other Covid-19 vaccine candidates in India

Drugs Controller General of India VG Somani gave the green light for the emergency-use of two coronavirus vaccines, one developed by AstraZeneca and Oxford University and the other by local company Bharat Biotech.
A health worker takes part in a dry run or a mock drill for Covid-19 coronavirus vaccine delivery at a model vaccination centre at Ansari Road in New Delhi on Saturday.(Sanchit Khanna/HT Photo)
A health worker takes part in a dry run or a mock drill for Covid-19 coronavirus vaccine delivery at a model vaccination centre at Ansari Road in New Delhi on Saturday.(Sanchit Khanna/HT Photo)
Updated on Jan 04, 2021 09:09 AM IST
Copy Link
Hindustan Times, New Delhi | By hindustantimes.com | Edited by Meenakshi Ray

News updates from Hindustan Times: Adar Poonawalla thanks DCGI after Covishield gets final approval for restricted use in India and all the latest news

Here are today’s top news, analysis and opinion at 1 PM. Know all about the latest news and other news updates from Hindustan Times.
(REUTERS)
(REUTERS)
Updated on Jan 03, 2021 01:17 PM IST
Copy Link
Hindustan Times, New Delhi | By hindustantimes.com

Covishield vs Covaxin against Covid-19: All you need to know

With more than one vaccine now approved for emergency use, the scope of India’s first phase vaccination in which the frontline workers will be vaccinated at free of cost gets widened.
Union Health Minister Harsh Vardhan visits Guru Teg Bahadur Hospital to review the dry run drill for administering Covid-19 vaccine, in New Delhi.(PTI)
Union Health Minister Harsh Vardhan visits Guru Teg Bahadur Hospital to review the dry run drill for administering Covid-19 vaccine, in New Delhi.(PTI)
Updated on Jan 03, 2021 08:33 PM IST
Copy Link
Hindustan Times, New Delhi | By hindustantimes.com | Edited by Poulomi Ghosh

Covid-19 vaccine update: Pan-India dry run on Saturday, WHO approves Pfizer’s candidate

The European Union (EU) will review a request by Pfizer’s German partner, BioNTech SE, for an additional vaccine dose from each vial, instead of the five currently approved.
The Pfizer Covid-19 vaccine has been approved by several countries (REUTERS)
The Pfizer Covid-19 vaccine has been approved by several countries (REUTERS)
Updated on Jan 01, 2021 10:58 AM IST
Copy Link
Hindustan Times, New Delhi | By hindustantimes.com | Edited by Karan Manral

India will have Covid-19 vaccine within days: AIIMS director

Pune-based SII has sought emergency approval for the vaccine--Covishield-- developed along with global pharma giant AstraZeneca and Oxford University.
India has a ‘robust plan’ for vaccination and is going to roll out vaccines for a large part of its population ‘in the near future’, AIIMS Delhi Director Dr Randeep Guleria said.(ANI photo)
India has a ‘robust plan’ for vaccination and is going to roll out vaccines for a large part of its population ‘in the near future’, AIIMS Delhi Director Dr Randeep Guleria said.(ANI photo)
Updated on Dec 31, 2020 09:06 AM IST
Copy Link
Hindustan Times, New Delhi | By hindustantimes.com | Edited by Prashasti Singh

Covid-19 vaccine updates: India likely to decide on first vaccine this week, South Korea seeks Moderna’s candidate

On Monday, the United States and Mexico commenced phase 3 trials of the vaccine candidate of Novovax, an American biotech firm.
A medical worker receives the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine at Santa Maria hospital in Lisbon, Portugal, December 28, 2020. REUTERS/Pedro Nunes
A medical worker receives the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine at Santa Maria hospital in Lisbon, Portugal, December 28, 2020. REUTERS/Pedro Nunes
Updated on Dec 29, 2020 09:32 AM IST
Copy Link
Hindustan Times, New Delhi | By hindustantimes.com | Edited by Karan Manral

‘300 million doses by July’: SII chief Adar Poonawalla on Covishield

Hinting at approval from British and Indian governments to approve shots for emergency use, Poonawalla said, “You will be hearing some good news from the UK very soon.”
Men walk past a mural of frontline workers amid the spread of the coronavirus disease in Mumbai, India.(REUTERS)
Men walk past a mural of frontline workers amid the spread of the coronavirus disease in Mumbai, India.(REUTERS)
Updated on Dec 28, 2020 08:05 PM IST
Copy Link
Hindustan Times, New Delhi | By hindustantimes.com | Edited by Arpan Rai

Covid-19 vaccine update: Pfizer applies for EUA in Japan, FDA to approve Moderna candidate

Oxford University said on Thursday its candidate has shown better immune response when a two full-dose regime is given, rather than a full-dose followed by a half-dose booster.
Pfizer has developed its vaccine candidate with BioNTech SE (FILE PHOTO)
Pfizer has developed its vaccine candidate with BioNTech SE (FILE PHOTO)
Updated on Dec 18, 2020 10:05 AM IST
Copy Link
Hindustan Times, New Delhi | By hindustantimes.com | Edited by Karan Manral

Pfizer, Serum Institute and Bharat Biotech apply for EUA in India: Here’s what might happen next

America’s Pfizer was the first firm to apply for EUA in India. Serum Institute and Bharat Biotech, both Indian firms, followed next.
Vials labelled
Vials labelled "COVID-19 Coronavirus Vaccine" are placed on dry ice in this illustration taken, December 4, 2020. REUTERS/Dado Ruvic/Illustration
Updated on Dec 08, 2020 02:27 PM IST
Copy Link
Hindustan Times, New Delhi | By hindustantimes.com | Edited by Karan Manral

Covid-19 vaccine update: Serum Institute of India seeks emergency use approval for Covishield, Sputnik V phase 2 trials begin in Pune

On Sunday, Indonesia received 1.2 million doses of the vaccine candidate of China’s Sinovac. The first shot of Pfizer’s vaccine, meanwhile, is likely to be administered to people in the United Kingdom on Tuesday.
Boxes containing the vials of AstraZeneca's COVISHIELD, coronavirus disease (COVID-19) vaccine are seen inside a cold room at the Serum Institute of India, in Pune, India, 30 November 2020. Picture taken November 30, 2020. REUTERS/Francis Mascarenhas
Boxes containing the vials of AstraZeneca's COVISHIELD, coronavirus disease (COVID-19) vaccine are seen inside a cold room at the Serum Institute of India, in Pune, India, 30 November 2020. Picture taken November 30, 2020. REUTERS/Francis Mascarenhas
Updated on Dec 07, 2020 08:17 AM IST
Copy Link
Hindustan Times, New Delhi | By hindustantimes.com | Edited by Karan Manral

SII seeks emergency use authorisation for Oxford Covid vaccine Covishield in India

A day earlier, the Indian arm of US pharmaceutical giant Pfizer became the first to seek a similar approval from India’s drug regulator for its own Covid-19 vaccine in the country, after securing such clearance in the UK and Bahrain.
Based on phase two and three clinical trial results, the SII with the help of the ICMR will pursue early availability of the vaccine for India, the country’s apex health research body had said last month.(Reuters file photo. Representative image)
Based on phase two and three clinical trial results, the SII with the help of the ICMR will pursue early availability of the vaccine for India, the country’s apex health research body had said last month.(Reuters file photo. Representative image)
Updated on Dec 07, 2020 12:42 AM IST
Copy Link
New Delhi | By Press Trust of India| Posted by: Harshit Sabarwal

Govt never spoke about vaccinating the entire country, says health ministry

Bhushan also said that the average daily positivity rate in India has been 3.72 per cent and with 211 cases per million, India has the lowest cases per million count “among all the big nations.”
Health Secretary Rajesh Bhushan said that all subjects sign a consent form before the trials that detail all the possible adverse effects of the vaccine inoculation.(HT Photo)
Health Secretary Rajesh Bhushan said that all subjects sign a consent form before the trials that detail all the possible adverse effects of the vaccine inoculation.(HT Photo)
Updated on Dec 01, 2020 06:28 PM IST
Copy Link
Hindustan Times, New Delhi | By hindustantimes.com | Edited by Srivatsan K C

SII to sue man over claims of Covishield side effects

When contacted, a spokesperson for Sri Ramachandra Institute of Higher Education and Research said the institute had received the notice, but declined to elaborate.
The man has served a legal notice on Pune-based SII, claiming to have suffered a virtual neurological breakdown and impairment of cognitive functions, seeking Rs 5 crore in compensation and a halt to the trial.(REUTERS)
The man has served a legal notice on Pune-based SII, claiming to have suffered a virtual neurological breakdown and impairment of cognitive functions, seeking Rs 5 crore in compensation and a halt to the trial.(REUTERS)
Published on Nov 30, 2020 02:29 AM IST
Copy Link
Hindustan Times, Chennai/New Delhi | By HT Correspondent and PTI, Chennai/new Delhi

News updates from Hindustan Times: Serum Institute pauses Covishield vaccine trials in India and all the latest news

Here are today’s top news, analysis and opinion. Know all about the latest news and other updates from Hindustan Times.
A research scientist works inside a laboratory of India’s Serum Institute, the world’s largest maker of vaccines.
A research scientist works inside a laboratory of India’s Serum Institute, the world’s largest maker of vaccines.
Updated on Sep 10, 2020 05:02 PM IST
Copy Link
Hindustan Times, New Delhi | By hindustantimes.com

Serum Institute pauses Covishield vaccine trials in India

UK-based pharma giant AstraZeneca paused vaccine trials after one of the recipients in the United Kingdom developed an ‘unexplained illness’ after being given a dose of the vaccine.
A research scientist works inside a laboratory of India's Serum Institute, the world's largest maker of vaccines.(Reuters image)
A research scientist works inside a laboratory of India's Serum Institute, the world's largest maker of vaccines.(Reuters image)
Updated on Sep 10, 2020 04:10 PM IST
Copy Link
Hindustan Times, New Delhi | By hindustantimes.com | Edited by Prashasti Singh

Phase 2 trial of Oxford Covid-19 vaccine candidate set to begin today

The observer-blind, randomised controlled study to determine the safety and immunogenicity of ‘‘Covishield’‘ on healthy Indian adults will begin at Bharati Vidyapeeth Medical College and Hospital in Pune.
Serum Institute of India has partnered with British-Swedish pharma company AstraZeneca for manufacturing the Covid-19 vaccine candidate, developed by the University of Oxford.(Reuters file photo)
Serum Institute of India has partnered with British-Swedish pharma company AstraZeneca for manufacturing the Covid-19 vaccine candidate, developed by the University of Oxford.(Reuters file photo)
Updated on Aug 25, 2020 07:41 AM IST
Copy Link
New Delhi, Delhi | By Press Trust of India | Posted by Shivani Kumar
SHARE
Story Saved
×
Saved Articles
My Reads
Sign out
New Delhi 0C
Sunday, October 24, 2021